Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated May 12, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Amended on May 25, 2017 – the version known today is shown.

You are looking at Q1 2017. Go to the latest filing (Q3 2026)

8.4B USDQ1 2017
Total value of stock positions
8.4B USD
Positions
41
Share of the ten largest
69.2%

The ten largest positions Q1 2017

  1. Cheniere Energy Inc 12.2%unchanged
  2. Viasat Inc 10.0%unchanged
  3. Twenty First Centy Fox Inc 7.3%unchanged
  4. Colony Northstar Inc 7.3%new
  5. Synchrony Financial 7.2%▼ −14.5%
  6. Allergan PLC 6.9%▼ −29.1%
  7. Qorvo Inc 5.8%new
  8. Dell Technologies 4.3%▼ −15.0%
  9. Pbf Energy Inc 4.1%unchanged
  10. Theravance Biopharma Inc 4.0%unchanged
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q1 2017

Positions Q1 2017 per 13F filing, 2 of 2
Symbol Weight Shares Reported value Change Held since
Forward Pharma A/S 1.4% 5,575,407 119.9M USD +3.9% increased Q4 2014 10 quarters
Cascadian Therapeutics Inc 0.4% 8,721,079 36.1M USD +109.3% increased Q4 2016 2 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 59.2M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Biopharma Inc principal 30.0M USD 37.8M USD
  • Theravance Inc principal 22.5M USD 21.4M USD

Breakdown by sector

  • Technology 7.8%
  • Financials 7.2%
  • Health Care 3.3%
  • Industrials 0.2%
  • not in our coverage 81.5%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close